Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY13524 A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCRaß+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Transplantation & Cellular Therapy Consortium (PTCTC) PIDTC \"CSIDE\" Protocol (Conditioning SCID Infants Diagnosed Early) PTCTC NMD 1801 The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants. Study Information
STUDY16060 A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients The primary aim of this study is to examine the safety of administration of the unlicensed investigational NCBP HPC-CORD BLOOD products in a multi-institution setting. Therefore, the study will evaluate prospectively the incidence of serious adverse reactions as well as the incidence of all infusion related reactions after administration of the unlicensed, investigational NCBP CBU. Study Information
STUDY17172 A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy. Study Information
STUDY17261 A Phase 1b Dose Escalation Study Of Metabolically Fit Cd19 Chimeric Antigen Receptor (Car) T Cells With Cd34 Selection Markers In Adult Patients With Relapsed Or Refractory Cd19 B Cell Non Hodgkin Lymphoma And Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 1) Determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended phase 2 dose (RP2D) of CD19-CD34t metabolically programmed CAR-T cells. 2) Determine the feasibility of manufacturing a CD19-CD34t metabolically programmed CAR-T cell therapy within 20% of the target dose level. 3) Assess the safety of administering escalating doses of a CD19-CD34t metabolically programmed CAR-T cell therapy following conditioning chemotherapy with cyclophosphamide and fludarabine. Study Information
STUDY18161 ACCESS: A Multi Center, Phase II Trial of HLA Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post Transplantation Cyclophosphamide for Patients with Hematologic Malignancies. To determine overall survival (OS) at one year following transplantation of a PBSC product from a MMUD using PTCy based GVHD prophylaxis Study Information